About Us

Introducing IMG-AbS™

ImmunoGenes' patented technology platform IMG-AbS™, is an FcRn technology using genetically modified animals that overexpress the neonatal Fc Receptor (FcRn). Because of FcRn's role in antigen presentation, the company's animals are able to mount a strong immune response against weakly immunogenic targets.

Learn More

Partnerships

In addition to the collaborations listed on this page, ImmunoGenes has completed agreements with major private companies that remain undisclosed that target other mammals with the capability to provide large quantities of polyclonal antibodies for a variety of medical purposes.

2013

ImmunoGenes AG announced a strategic collaboration with Public Health England (PHE) to address unmet healthcare needs caused by the bacterium Clostridium difficile (C. difficile), including diarrhea, intestinal inflammation, and sometimes serious illness for which there is no effective treatment available



PHE_LOGO

2012

ImmunoGenes has entered into research collaboration with the Feske Lab at NYU School of Medicine. Under the collaboration, The Feske Lab will identify key targets in calcium release activated calcium (CRAC) channels, and ImmunoGenes will generate antibodies against those targets using its proprietary FcRn-overexpressing transgenic (tg) mice.

 

2011

ImmunoGenes has entered into research collaborations with the following companies to explore the opportunities provided by ImmunoGenes' proprietary FcRn-overexpressing tg mice to generate antibodies against difficult antigen targets, which are of significant interest to developers of novel therapeutics and diagnostics.

Amgen

BMS

2009

In December 2009, ImmunoGenes signed a collaboration with The Roslin Institute of the University of Edinburgh to develop specialized sheep that use ImmunoGenes' proprietary technology to produce higher than normal levels of polyclonal antibodies. Under the partnership, The Roslin Institute will create sheep transgenic for the neonatal Fc receptor for IgG (FcRn). In addition to the scientific collaboration, the agreement also grants ImmunoGenes an exclusive license to commercialize the resulting transgenic animals.

BMS

 

2008

ImmunoGenes is the leader of consortium which develops FcRn transgenic technologies in rabbits. In this context ImmunoGenes entertains strategic collaboration with leading academic institutions including Eötvös Loránd University, Budapest and Agriculture Biotechnology Center, Gödöllö.

Partner

Our Partner